The competition authority issues its decision on the merger of Mehiläinen and Docrates Cancer Center – the process will proceed as planned

- We are pleased that the Docrates acquisition will be completed and enables us to offer comprehensive services to our customers when it comes to cancer. The acquisition expands our services also internationally. As a pioneer in cancer treatments, Docrates has built a unique treatment path that is sought after by customers from all over the world, says Johanna Asklöf, Business Line Director from Mehiläinen.

Together, Mehiläinen and Docrates Cancer Center will be able to serve customers more comprehensively than before.

- The strong development of private cancer hospital operations and the provision of high-quality cancer treatments to both Finnish and international customers will continue also in the future, Asklöf says.

The patient-physician relationships of Docrates' customers and all of the services will continue as usual at Docrates Cancer Center. After the acquisition, the hospital's personnel and private practitioners will continue to work as existing employees and private practitioners under their original contracts.

Docrates Cancer Center is specialised in the diagnostics, treatment and follow-up of cancer. As a private cancer hospital, Docrates is a pioneer in Europe and the only one of its kind in the Nordic countries. In Docrates’ operations, the emphasis is on the personalisation and timeliness of cancer treatments, as well as quality, education and research. In 2023, Docrates Cancer Center had 19,000 customer visits.